araag2/HINT huggingface dataset:
Clinical trial NCT00057785 (phase 2, status: completed)
Conditions: head and neck cancer, oral complications of radiation therapy, radiation toxicity
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, A36.89, B01.89, B02.9, B05.89, B06.89, B26.89, K94.30, K62.7, G62.82, N46.024, N46.124, T66.XXXS, Z57.1, N52.35
Drugs: cisplatin, fluorouracil
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage I-IVB squamous cell carcinoma of the nasopharynx

               -  WHO I-III

               -  No stage IVC disease

               -  No evidence of distant metastasis

          -  Measurable or evaluable disease

          -  Must have been treated with primary radiotherapy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  White blood cell count (WBC) at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Not specified

        Renal

          -  Creatinine no greater than 1.6 mg/dL

          -  Creatinine clearance at least 60 mL/min

        Other

          -  Not pregnant (If stage T2b or greater or node-positive disease)

          -  Negative pregnancy test (If stage T2b or greater or node-positive disease)

          -  No other prior head and neck cancer

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer

          -  No active untreated infection

          -  No other major medical or psychiatric illness that would preclude study entry

          -  Nutritional and general physical condition compatible with radiotherapy NOTE: *If
             stage T2b or greater or node-positive disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 6 months since prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  More than 6 months since prior radiotherapy for head and neck cancer

        Surgery

          -  No prior head and neck surgery to the primary tumor or lymph nodes except incisional
             or excisional biopsies

        Other

          -  No other concurrent experimental therapy for cancer

          -  No amifostine or pilocarpine during or for 3 months after radiotherapy
Clinical trial NCT00400829 (phase 2, status: completed)
Conditions: recurrent non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: eribulin mesylate
SMILES: [H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

          -  Stage IIIB or IV disease

          -  Recurrent or progressive disease

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques OR ≥ 10 mm by spiral CT scan

          -  Must have received prior treatment with platinum-based therapy and a taxane

          -  Asymptomatic brain metastasis allowed provided off steroids for > 2 weeks

          -  Zubrod performance status (PS) ≤ 2 OR Karnofsky PS 60-100%

          -  Life expectancy > 3 months

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin ≤ 2.0 mg/dL

          -  AST/ALT ≤ 2.5 times upper limit of normal

          -  Creatinine normal OR creatinine clearance ≥ 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No neuropathy ≥ grade 2

          -  No uncontrolled illness including, but not limited to, any of the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness or social situations that would preclude study compliance

          -  No other concurrent investigational agents

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
             and recovered

          -  At least 2 weeks since prior radiotherapy, including palliative radiotherapy, and
             recovered

          -  No more than 2 prior chemotherapy regimens for NSCLC in the metastatic or adjuvant
             setting

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

        Exclusion Criteria:

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to E7389
Clinical trial NCT00329433 (phase 2/phase 3, status: completed)
Conditions: deep venous thrombosis
ICD codes: I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8
Drugs: desirudin (iprivask™), heparin
SMILES: O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who are scheduled for elective Cardiac or Thoracic Surgery.

          -  Age > 18 years of age.

        Exclusion Criteria:

          -  Patients with a clinical suspicion or a documented history of DVT/PE

          -  Patients who may require anticoagulation during the post-op period. (i.e. Patients
             with a history of A-fib, scheduled for a MAZE procedure or placement of a mechanical
             valve, or those on Coumadin/IV heparin preoperatively)

          -  Patients who have a history of HIT or if there is a suspicion of the patient having
             HIT pre-operatively.

          -  Documented allergy to heparin, desirudin, or lepirudin

          -  Patients with a history of coagulation disorder

          -  Platelet count< 100 X109 /dl

          -  Active bleeding

          -  Serum Creatinine ≥ 1.5 mg/dl or CrCl ≤ 30 ml/min

          -  Patients with a baseline coagulopathy (INR > 1.5 or aPTT > 45 sec)

          -  Patients with liver disease

          -  Pregnancy

          -  Patients who require ventricular assist devices before or after surgery
Clinical trial NCT00627354 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: etoposide, mitoxantrone hydrochloride, prednisone, vinorelbine tartrate
SMILES: OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Metastatic progressive disease meeting the following criteria:

                    -  Increase in measurable lesions > 25%

                    -  Increase in bone lesions > 25%

                    -  Biological progression rate of PSA > 4 ng/mL

          -  Received docetaxel as first-line chemotherapy

          -  Received at least 1 prior regimen of hormone therapy

          -  Pain > 2 on Visual Analog Scale or continuing level 2 analgesics

          -  No symptomatic or evolutionary CNS disease

        PATIENT CHARACTERISTICS:

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine ≤ 1.5 times normal

          -  Alkaline phosphatase ≤ 2 times normal (unless bone metastases are present)

          -  Transaminases ≤ 1.5 times normal

          -  Bilirubin ≤ 1.5 times normal

          -  No prior malignancy except basal cell skin cancer

          -  No peripheral neuropathy or severe neuropathy ≥ grade 2

          -  No other severe lung, hepatic, renal, or digestive disease that would be complicated
             by treatment

          -  LVEF > 50%

          -  No history of peptic ulcer, unstable diabetes, or other contraindication to using
             steroids

          -  No severe infection requiring antibiotics

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 8 weeks since prior metabolic radiotherapy

          -  More than 4 weeks since prior external radiotherapy

          -  At least 1 month since prior docetaxel-based chemotherapy

          -  At least 1 month since prior antiandrogen therapy in the case of complete hormonal
             blockage

          -  No participation in another clinical trial within the past 30 days
Clinical trial NCT00483977 (phase 2, status: terminated)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: oxycodone, placebo, pf-000592379
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    met criteria for study futility at interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female of any race

          -  Between the ages of 18 and 75 years

          -  Knee Pain due to osteoarthritis

        Exclusion Criteria:

          -  Pregnant

          -  Participation in a clinical trial for an investigational drug and/or agent within 30
             days prior to baseline

          -  History of malignancy, convulsions, chronic infections, arthroscopy of the worst knee
             within the past year
Clinical trial NCT00476463 (phase 2, status: completed)
Conditions: hepatitis b virus, hiv infections
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, Z21
Drugs: emtricitabine
SMILES: NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Documented HIV infection (positive serology for HIV-1 and detectable HIV-1 RNA)

          -  Age 18 - 70 years

          -  HBV DNA > 106 copies/ml

          -  HBsAg positive for > 6 months

        In case documented duration of HBsAg seropositive is less than 6 months (this situation is
        most likely to occur in patients newly presenting to the HIV-outpatient clinic) the patient
        is eligible if the patient is:

          1. HBsAg positive and

          2. HBc core IgM antibody negative and

          3. the liver biopsy gives evidence for a chronic active hepatitis. Thus making it likely
             that this patient has acquired the HBV infection more than 6 months ago.

               -  ALT < 10 x ULN

               -  Creatinine <= 2.0mg/dl

               -  Platelet count >= 50,000/mm3

               -  HIV-1 therapy naive

               -  No prior exposure to anti-HBV agents (LAM, adefovir, TDF) although prior IFN
                  treatment allowed

        Exclusion Criteria:

          -  HCV-RNA positive or Anti-HAV IgM positive

          -  Acute hepatitis (serum ALT > 1000 U/L)

          -  Prior LAM, TDF, or ADV therapy

          -  Active opportunistic infection

          -  Other causes of chronic liver disease identified ( autoimmune hepatitis,
             haemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency)

          -  Concurrent malignancy requiring cytotoxic chemotherapy

          -  Decompensated or Child's C cirrhosis

          -  Alfa-fetoprotein (AFP) > 3X ULN (unless negative CT scan or MRI within 3 months of
             entry date)

          -  Pregnancy or lactation

          -  Any other condition which in the opinion of the investigator might interfere with
             compliance or outcome of the study
Clinical trial NCT00295867 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: zoledronic acid
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria

          1. Women > 18 years of age with histologically or cytologically confirmed stage I, II or
             III breast cancer.

          2. If adjuvant chemotherapy is recommended, it must be completed before study start.

          3. Bone marrow aspirate positive by IC/FC assay

             a. Definition of positive: > 4 MM/ml b. Timing of bone marrow aspiration to determine
             study eligibility: i. If patient is to receive either no adjuvant therapy or hormonal
             therapy alone, the aspiration may be performed at diagnosis as part of the large MM
             study at University of California, San Francisco, or following diagnosis if the
             patient received initial surgery elsewhere. This is also true for patients who have
             surgery following neoadjuvant therapy for breast cancer.

             ii. If the patient is to receive adjuvant chemotherapy, the aspiration will be
             performed at least three weeks after chemotherapy has been completed.

          4. Adequate renal function as defined by:

             a. Creatinine must be < upper limit of normal

          5. Normal liver function tests including total bilirubin, alkaline phosphatase, and
             aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT)

          6. Ability to understand and sign informed consent.

          7. Concomitant hormonal therapy is allowed

          8. Concomitant radiation therapy is allowed

          9. Patients who have had surgery following neoadjuvant chemotherapy or hormonal therapy
             are eligible to participate in this trial

        Exclusion Criteria

          1. History of allergy to bisphosphonates. Acute phase reactions occur in up to 24% of
             patients and disappear with subsequent dosing. An acute phase reaction does not
             qualify as an allergic reaction.

          2. History of renal insufficiency. Renal insufficiency is defined by a serum creatinine
             greater than the upper limit of normal or a creatinine clearance < 50 mL/min due to
             any underlying cause.

          3. Karnofsky Performance status < 90%.

          4. Any significant medical condition that might interfere with treatment.

          5. Women participating in this study are not allowed to receive other bisphosphonate
             therapy during the study period, either oral or intravenous.

          6. Patients who are pregnant
Clinical trial NCT01253408 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: dronabinol, placebo
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-75 years

          -  Positive for IBS symptoms by Rome III criteria

          -  No prior abdominal surgery (except appendectomy or cholecystectomy)

          -  Baseline Geometric Center at 24 hours is greater/equal to 2.0

          -  Baseline Geometric Center at 48 hours is greater/equal to 3.9

        Exclusion Criteria:

          -  Patients with significant depression (score of greater than 10 on Hospital and Anxiety
             Inventory)

          -  Patients with anxiety (score of greater than 10 on Hospital and Anxiety Inventory)
             will not be allowed to participate. However, patients on stable doses of selective
             serotonin re-uptake inhibitors (SSRIs) or low dose of tricyclic antidepressants will
             be eligible.
Clinical trial NCT00582855 (phase 2, status: terminated)
Conditions: mild alzheimer's disease, amnestic mild cognitive impairment
ICD codes: Z73.82, G31.84, M10.38, M10.30, M10.311, M10.312, M10.319
Drugs: aqw051, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to give written informed consent

          -  Meet the diagnostic criteria for either amnestic mild cognitive impairment (amnestic
             MCI) or mild Alzheimer's Disease (AD).

          -  Structural brain scan within the last 6 months prior to randomization that indicates
             no other underlying disease, in particular no evidence for vascular pathology except
             for normal age-related white matter/incidental white matter changes which is normal
             for this age group.

          -  Daily contact with a primary caregiver/partner

        Exclusion Criteria:

          -  Immune therapy targeting Alzheimer beta amyloid within the last 12 months

          -  Institutionalized

          -  Disability that may prevent completion of all study requirements (e.g., blindness,
             deafness, or communication difficulty)

          -  Reported use of tobacco products in the previous 3 months or have a urine cotinine
             level greater than 500 ng/ml

          -  Past medical history of clinically significant electrocardiogram (ECG) abnormalities
             or a family history (grandparents, parents, and siblings) of prolonged QT-interval
             syndrome

          -  History or current diagnosis of conditions specified in the protocol.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00473889 (phase 2/phase 3, status: terminated)
Conditions: stage iiib or iv non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: vorinostat, comparator: paclitaxel, comparator: carboplatin, comparator: placebo
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], CN(C)C(=N)NC(N)=N
Reason stopped: 
    the study was terminated based on the recommendation by the dsmb following a pre-planned
    protocol interim analysis because the endpoint was not achieved.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females at least 18 years of age who have confirmed diagnosis of Non-small
             Cell Lung Cancer

          -  Patients with no systemic prior systemic treatment for lung cancer except patients at
             least 12 months from prior adjuvant therapy

          -  Adequate bone marrow,kidney and liver function

          -  Must be recovered and at least 4 weeks from major surgery or radiation

          -  ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1

          -  Men and women must agree to use birth control during the study

          -  Women able to have children must have a negative pregnancy test 14 days before study
             enrollment

        Exclusion Criteria:

          -  Patients with prior treatment with other investigational agents less than 4 weeks
             before study enrollment

          -  Pregnant or nursing female patients

          -  Patients who are HIV positive

          -  Patients who have Hepatitis A, B, or C

          -  Patients unable to take study medication by mouth

          -  Patients with untreated brain cancer

          -  Patient eligible for treatment with bevacizumab and for whom bevacizumab is available
Clinical trial NCT00694707 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: placebo, cariprazine, risperidone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 to 60 years of age.

          -  Meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
             criteria for schizophrenia (paranoid type, disorganized type, catatonic type, or
             undifferentiated type) based on a Structured Clinical Interview for DSM-IV (SCID).

          -  Total Positive and Negative Syndrome Scale (PANSS) score ≥ 80 and ≤ 120.

          -  Diagnosis of schizophrenia for at least 1 year.

        Exclusion Criteria:

          -  Abnormalities on physical examination or abnormal vital signs, electrocardiogram, or
             clinical laboratory values.

          -  First episode of psychosis.
Clinical trial NCT00411450 (phase 2, status: completed)
Conditions: colon cancer, colorectal cancer, rectal cancer, cancer, metastatic cancer, metastatic colorectal cancer, oncology
ICD codes: C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: folfiri
SMILES: FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of metastatic adenocarcinoma of the colon or rectum

          -  Available paraffin-embedded tumor tissue

          -  Failure of first line treatment containing fluoropyrimidine and oxaliplatin based
             chemotherapy with bevacizumab for mCRC

          -  Measurable disease

          -  Adequate hematologic, renal, hepatic and metabolic function

        Exclusion Criteria:

          -  Radiotherapy ≤ 2 weeks prior to Day 1 of Cycle 1

          -  Unresolved toxicity(ies) from prior anti cancer therapy that, in the opinion of the
             investigator, precludes the subject from study enrollment

          -  Prior irinotecan therapy, anti epidermal growth factor receptor (EGFr) therapy, or
             vaccine for the treatment of mCRC

          -  CYP3A4 enzyme inducers, inhibitors, and substrates (eg, phenytoin, phenobarbital,
             carbamazepine, ketoconazole, rifampin, rifabutin, and St. John's Wort) ≤ 2 weeks prior
             to Day 1 of Cycle 1

          -  Infection requiring systemic anti infectives completed ≤ 2 weeks prior to Day 1 of
             Cycle 1

          -  Clinically significant cardiovascular disease

          -  History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)

          -  Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event ≤
             8 weeks prior to Day 1 of Cycle 1

          -  Any significant bleeding ≤ 6 weeks prior to Day 1 of Cycle 1, per the investigator's
             judgement

          -  Gastroduodenal ulcer(s) determined by endoscopy to be active or uncontrolled
             gastrointestinal ulcer ≤ 4 weeks prior to Day1 of Cycle 1

          -  Any co-morbid disease or condition that could increase the risk of toxicity (eg,
             dihydropyrimidine deficiency, significant ascites, or pleural effusion)

          -  Major surgery (requiring general anesthesia), open biopsy, or significant traumatic
             injury ≤ 4 weeks prior to Day1 of Cycle 1. Subjects must have recovered from surgery
             and have no significant complications